Sanara MedTechSMTI +1.38%72 EBITDA Margin % is 10.01% as of Mar. 2026. GuruFocus rates SMTI with a GF Score™ of 72/100 and a GF Value™ of $45.52 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Sanara MedTech ranks better than 51.47% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sanara MedTech's EBITDA for the
three
months ended in Mar. 2026 was $2.8 Mil. Sanara MedTech's Revenue for the
three
months ended in Mar. 2026 was $27.8 Mil. Therefore, Sanara MedTech's EBITDA margin for the quarter that ended in Mar. 2026 was 10.01%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sanara MedTech EBITDA Margin % Related Terms
Sanara MedTech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sanara MedTech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SMTI vs PDEX, UTMD, EMBC: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Sanara MedTech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanara MedTech EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sanara MedTech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanara MedTech (SMTI) has a EBITDA Margin % of 10.01% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sanara MedTech and its competitors. According to the industry distribution chart, Sanara MedTech ranks #396 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 48.5%.
Is Sanara MedTech's EBITDA Margin % too high?
Sanara MedTech's current EBITDA Margin % is 10.01%. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Sanara MedTech's value of 10.01% is 33.9% above this industry median. Based on the distribution chart, Sanara MedTech ranks #396 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sanara MedTech has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanara MedTech's EBITDA Margin % compare to PDEX and UTMD?
According to the Medical Devices & Instruments industry distribution chart, Sanara MedTech ranks #396 out of 816 companies for EBITDA Margin %. This puts Sanara MedTech in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Sanara MedTech's value of 10.01% is 33.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanara MedTech's current EBITDA Margin % of 10.01% is 33.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sanara MedTech and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanara MedTech's current EBITDA Margin % is 10.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanara MedTech stock overvalued right now?
Based on GuruFocus' analysis, Sanara MedTech (SMTI) is currently considered Possible Value Trap. The stock's GF Value™ is $45.52, compared to a current price of $23.19 — trading 49.1% below its estimated fair value. The current EBITDA Margin % is 10.01% and 33.9% above the Medical Devices & Instruments industry median of 7.48. Sanara MedTech's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sanara MedTech (SMTI), the current EBITDA Margin % is 10.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanara MedTech (SMTI) Overvalued in 2026?
Based on GuruFocus' analysis, Sanara MedTech stock appears to be undervalued.
The current stock price of $23.19 is trading 49.1% below its estimated GF Value™ of $45.52.
GuruFocus considers Sanara MedTech to be Possible Value Trap.
Key valuation signals for SMTI:
EBITDA Margin %: 10.01%
GF Value™: $45.52 vs. price of $23.19 (49.1% below fair value)
Industry Position: 33.9% above the Medical Devices & Instruments median (#396 of 816)
No single metric tells the full story. See the SMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
72GF Score
Get the complete analysis for SMTI
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SMTI has been successfully added to your 
